In support of this hypothesis, we have identified an extensive program of altered molecular markers in skeletal muscle, including transforming growth factor beta 1 (TGF-β1) and mothers against decapentaplegic homolog 8 (SMAD8), that are consistently increased across a broad sampling of ALS patients [16–21]. This evidence concerns the gene SMAD9 and amyotrophic lateral sclerosis.